Thymosin Alpha-1

Overview

Thymosin Alpha-1 (Ta1) is a 28-amino-acid peptide originally isolated from thymosin fraction 5, a partially purified extract of calf thymus tissue, by Allan Goldstein and colleagues at the George Washington University in 1977. The thymus gland plays a central role in T-cell maturation and immune system development, and thymosin alpha-1 was identified as one of the key bioactive peptides responsible for the immune-enhancing properties of thymic extracts.

Thymosin alpha-1 holds a unique position in the peptide landscape: it is one of the few research peptides to have achieved regulatory approval for clinical use. Marketed as Zadaxin (thymalfasin) by SciClone Pharmaceuticals, it has been approved in over 35 countries — predominantly in Asia, the Middle East, and South America — for the treatment of chronic hepatitis B and as an adjunct immunotherapy for various cancers. It received orphan drug designation from the U.S. FDA for hepatitis B and hepatocellular carcinoma, though it has not received full FDA approval in the United States.

With over 4,400 published clinical and preclinical studies and administration to over 500,000 patients worldwide, thymosin alpha-1 is among the most extensively characterized immunomodulatory peptides. Its clinical track record distinguishes it from most peptides discussed in the research community, providing a level of human safety and efficacy data that is uncommon in this space.

Structure and Sequence

Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn

• Molecular formula: C₁₂₉H₂₁₅N₃₃O₅₅
• Molecular weight: 3,108.3 g/mol (acetylated form)
• N-terminal modification: Acetylated serine (the N-terminal acetylation is important for biological activity)
• CAS Number: 62304-98-7
• Acidic character: pI of approximately 4.2, due to a high proportion of acidic residues (Asp, Glu)

The peptide is highly acidic with no disulfide bonds or post-translational modifications beyond N-terminal acetylation. It adopts a largely disordered structure in aqueous solution but assumes alpha-helical conformations in membrane-mimetic environments.

Mechanism of Action

Toll-like Receptor (TLR) Signaling

Thymosin alpha-1 acts as an endogenous regulator of innate immunity primarily through modulation of Toll-like receptor signaling:

• TLR9 and TLR2 activation — Ta1 signals through TLR9 and TLR2 on dendritic cells and macrophages, activating MyD88-dependent signaling cascades
• NF-kB and IRF-7 activation — Downstream signaling leads to activation of transcription factors that upregulate cytokine production
• Type I interferon induction — TLR9 activation by Ta1 induces interferon-alpha production, a key mediator of antiviral defense

Dendritic Cell Maturation

Ta1 promotes the maturation and functional activation of dendritic cells (DCs):

• Enhanced expression of MHC class I and II molecules
• Upregulation of co-stimulatory molecules (CD80, CD86)
• Increased antigen-presenting capacity
• Promotion of cross-presentation, enabling CD8+ T cell activation against intracellular pathogens and tumor antigens

T-Cell Immune Reconstitution

As a thymic peptide, Ta1 promotes T-cell development and function:

• Enhancement of T-cell maturation from precursor cells
• Restoration of T-cell subsets in immunocompromised states (post-chemotherapy, HIV, aging)
• Promotion of CD4+ and CD8+ T-cell differentiation
• Enhancement of T-cell receptor diversity

Natural Killer Cell Activation

Ta1 enhances natural killer (NK) cell cytotoxicity through:

• Upregulation of NK cell activating receptors
• Enhanced production of perforin and granzymes
• Increased interferon-gamma production by NK cells

Anti-inflammatory Balance

Despite its immune-stimulating properties, Ta1 also exhibits immunomodulatory (balancing) effects:

• Reduction of pro-inflammatory cytokine overproduction in sepsis models
• Downregulation of HMGB1 release
• Prevention of immune over-activation while maintaining pathogen clearance

Research Summary

Pharmacokinetics

Thymosin alpha-1 has well-characterized pharmacokinetics from clinical studies:

• Bioavailability: Approximately 80-90% following subcutaneous injection
• Peak plasma concentration: Reached within 1-2 hours after subcutaneous administration
• Half-life: Approximately 2 hours in plasma
• Distribution: Widely distributed; crosses into lymphoid compartments
• Metabolism: Degraded by tissue proteases; no hepatic cytochrome P450 involvement (low drug interaction potential)
• Clinical dosing: Standard clinical dose is 1.6 mg subcutaneously, administered twice weekly (as per Zadaxin prescribing information)
• Steady state: Achieved within the first week of twice-weekly dosing

The favorable pharmacokinetic profile — high bioavailability, predictable absorption, and lack of CYP-mediated metabolism — contributes to thymosin alpha-1's established clinical utility and safety record.

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Reconstitution

Dosing Schedule

Syringe Measurements (U-100 insulin syringe)

Cycle Guidelines

• Cycle length: 8-12 weeks (up to 16 weeks)
• Route: Subcutaneous injection
• Timing: Consistent daily timing
• Injection sites: Rotate between abdomen, thighs, and upper arms
• Note: Thymosin alpha-1 is approved as Zadaxin in several countries (not US/EU) for hepatitis B at 1.6 mg twice weekly

Common Discussion Topics

1. Immune reconstitution — Ta1 is frequently discussed for immune support in the context of chronic infections, post-chemotherapy immune recovery, and age-related immune decline (immunosenescence)
2. Approved clinical use — Its status as an approved pharmaceutical in over 35 countries provides a level of clinical validation unusual among peptides discussed in the research community
3. Cancer immunotherapy adjunct — Growing interest in combining Ta1 with checkpoint inhibitors and other immunotherapies
4. Infection management — Applications in chronic hepatitis B and C, HIV, and emerging infectious diseases including COVID-19
5. Vaccine enhancement — Potential as an immune adjuvant to improve vaccine responses, particularly in elderly or immunocompromised populations
6. Comparison with thymic peptides — Differentiation from related thymic peptides including thymosin beta-4 (TB-500), thymulin, and thymopoietin

Related Compounds

• TB-500 (Thymosin Beta-4) — another peptide from thymosin fraction 5, primarily studied for tissue repair rather than immune modulation
• LL-37 — an antimicrobial peptide that also bridges innate and adaptive immunity
• KPV — an anti-inflammatory peptide with complementary immunomodulatory properties
• Thymulin — a zinc-containing nonapeptide of thymic origin involved in T-cell differentiation
• Thymopoietin — a thymic peptide that induces T-cell differentiation markers